A Phase 1, First-in-human, Randomized, Double-blind Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of 9MW3811 in Healthy Adult Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 9MW 3811 (Primary)
Indications Pulmonary fibrosis; Solid tumours
Focus Adverse reactions; First in man
Sponsors Mabwell (Shanghai) Bioscience

Most Recent Events

12 Jun 2023 Status changed from not yet recruiting to recruiting.
28 Feb 2023 New trial record
27 Feb 2023 According to Mabwell media release, the company has received the official approval by the Australian Therapeutic Goods Administration (TGA) to conduct clinical trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight